; or (B) employees of contractors or subcontractors of the United States— (i) who are performing under a contract that directly supports the missions or activities of individuals described in subparagraph (A); and (ii) whose official duty stations are located overseas or are on permissive temporary duty travel outside of the continental United States. (3) the acquisition, use, or distribution of multiomic data, however compiled, that is commercially or publicly available. (e) Waiver authorities (1) In general The policy, guidance, and regulations established under subsection (b) shall allow the head of an Executive agency to waive any prohibition implemented in connection with such guidance on a case-by-case basis after consultation with the Federal entity. (2) Duration (A) In general Except as provided in subparagraph (B), a waiver granted under paragraph (1) shall last for a period of not more than one year. (B) Extension The head of an Executive agency may extend a waiver granted to an Executive agency under paragraph (1) one time, for a period up to 180 days after the date on which the waiver would otherwise expire, if such an extension is in the national security interests of the United States and the Executive agency submits to the appropriate congressional committees a notification of such waiver not later than 30 days after granting the waiver. (f) Determination of certain biotechnology entities (1) In general Not later than 180 days after the date of the enactment of this Act, the Federal entity shall develop a list of entities determined to be a biotechnology company of concern. The Federal entity shall define a biotechnology company of concern as any entity that— (A) is subject to the jurisdiction, direction, control, or operates on behalf of the government of a foreign adversary; (B) is to any extent involved in the manufacturing, distribution, provision, or procurement of biotechnology equipment or services